Published Online
on October 22, 2007

A more recent version of this article appeared on November 6, 2007

This Article Full Text (PDF) Data Supplement All Versions of this Article: 116/19/2101    most recent CIRCULATIONAHA.107.704759v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sakabe, M. Articles by Nattel, S. Search for Related Content PubMed PubMed Citation Articles by Sakabe, M. Articles by Nattel, S. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Atrial Fibrillation Dietary Fats Heart Failure Related Collections Remodeling Arrythmias-basic studies Arrhythmias, clinical electrophysiology, drugs

Submitted on March 21, 2007
Accepted on September 4, 2007

Omega-3 Polyunsaturated Fatty Acids Prevent Atrial Fibrillation Associated With Heart Failure but Not Atrial Tachycardia Remodeling

Masao Sakabe MD, PhD, Akiko Shiroshita-Takeshita MD, PhD, Ange Maguy PhD, Chloe Dumesnil BSc, Anil Nigam MD, Tack-Ki Leung MD, and Stanley Nattel MD^*

From the Department of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada (M.S., A.S.-T., A.M., C.D., A.N., T.-K.L., S.N.), and the Second Department of Internal Medicine, University of Toyama, Toyama, Japan (M.S.).

^* To whom correspondence should be addressed. E-mail: stanley.nattel{at}icm-mhi.org.

Background—There is epidemiological evidence that omega-3 polyunsaturated fatty acids (PUFAs) reduce the risk of atrial fibrillation (AF), but clinical data are conflicting. The present study assessed the effects of PUFA on AF in experimental models.

Methods and Results—We studied the effects of oral PUFA supplements in 2 experimental AF paradigms: electrical remodeling induced by atrial tachypacing (400 bpm for 1 week) and congestive heart failure–associated structural remodeling induced by ventricular tachypacing (240 bpm for 2 weeks). PUFA pretreatment did not directly change atrial effective refractory period (128±6 [mean±SEM] versus 127±2 ms; all effective refractory periods at 300-ms cycle lengths) or burst pacing–induced AF duration (5±4 versus 34±18 seconds). Atrial tachypacing dogs had shorter refractory periods (73±6 ms) and greater AF duration (1185±300 seconds) than shams (119±5 ms and 20±11 seconds; P<0.01 for each). PUFAs did not significantly alter atrial tachypacing effects on refractory periods (77±8 ms) or AF duration (1128±412 seconds). PUFAs suppressed ventricular tachypacing–induced increases in AF duration (952±221 versus 318±249 seconds; P<0.05) and attenuated congestive heart failure–related atrial fibrosis (from 19.2±1.1% to 5.8±1.0%; P<0.001) and conduction abnormalities. PUFAs also attenuated ventricular tachypacing–induced hemodynamic dysfunction (eg, left ventricular end-diastolic and left atrial pressure from 12.2±0.5 and 11.4±0.6 mm Hg, respectively, to 6.4±0.5 and 7.0±0.8 mm Hg; P<0.01) and phosphorylation of mitogen-activated protein kinases (extracellular-signal related and P38 kinase).

Conclusions—PUFAs suppress congestive heart failure–induced atrial structural remodeling and AF promotion but do not affect atrial tachycardia–induced electrical remodeling. The beneficial effects of PUFAs on structural remodeling, possibly related to prevention of mitogen-activated protein kinase activation, may contribute to their clinical anti-AF potential.

Key words: arrhythmia • atrium • fatty acids • heart failure

This article has been cited by other articles:

				K. Nishida, G. Michael, D. Dobrev, and S. Nattel Animal models for atrial fibrillation: clinical insights and scientific opportunities Europace, October 29, 2009; (2009) eup328v1. [Abstract] [Full Text] [PDF]

				J. H. Rennison and D. R. Van Wagoner Impact of Dietary Fatty Acids on Cardiac Arrhythmogenesis Circ Arrhythm Electrophysiol, August 1, 2009; 2(4): 460 - 469. [Full Text] [PDF]

				M. A. Crandall, D. J. Bradley, D. L. Packer, and S. J. Asirvatham Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies Mayo Clin. Proc., July 1, 2009; 84(7): 643 - 662. [Abstract] [Full Text] [PDF]

				G. Cocco and D. Chu Rimonabant may induce atrial fibrillation BMJ, June 12, 2009; 338(jun12_1): b1061 - b1061. [Full Text]

				E. B. Levitan, A. Wolk, and M. A. Mittleman Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: a population-based prospective study of middle-aged and elderly men Eur. Heart J., June 2, 2009; 30(12): 1495 - 1500. [Abstract] [Full Text] [PDF]

				G.-R. Li, H.-Y. Sun, X.-H. Zhang, L.-C. Cheng, S.-W. Chiu, H.-F. Tse, and C.-P. Lau Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K+currents and Na+current in human atrial myocytes Cardiovasc Res, February 1, 2009; 81(2): 286 - 293. [Abstract] [Full Text] [PDF]

				S. Nattel, B. Burstein, and D. Dobrev Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications Circ Arrhythm Electrophysiol, April 1, 2008; 1(1): 62 - 73. [Full Text] [PDF]

				B. Burstein and S. Nattel Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation J. Am. Coll. Cardiol., February 26, 2008; 51(8): 802 - 809. [Abstract] [Full Text] [PDF]